Streetbeat News

BSGM

Biosig Technologies Inc

Employees

59

Industry

Surgical and Medical Instrument Manufacturing

biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

BioSig Technologies has announced its intent to acquire the assets of Neuro-Kinesis Corporation. A non-binding letter of intent has been executed, with the purchase price to be paid in BioSig common stock. Neuro-Kinesis Corporation will provide $2.5M-$6M in unrestricted cash at closing. Due diligence will continue through the end of the year, and full disclosures will be made in the next proxy statement for a shareholder vote.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 1:47 pm

12 health care stocks experienced significant movements in Tuesday's after-market session. Notable gainers include Autonomix Medical (AMIX), Unicycive Therapeutics (UNCY), and Venus Concept (VERO). Significant losers include Calidi Biotherapeutics (CLDI), BioSig Technologies (BSGM), and ThermoGenesis Holdings (THMO).

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 8:31 pm

BioSig Technologies shares are trading lower after the company was notified by the Nasdaq Hearings Panel that its common stock will be delisted from the Nasdaq Stock Market due to non-compliance with the minimum stockholders' equity requirement.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 5:52 pm

BioSig Technologies (NASDAQ:BSGM) shares plummeted by 67% to $0.55 after the company announced it will be delisted from the Nasdaq Stock Market due to non-compliance with the minimum stockholders’ equity requirement. Trading will be suspended on Nasdaq starting June 12, and the stock will trade on the OTC Markets’ Pink Current Information tier under the symbol 'BSGM'. The company plans to appeal the decision.

Portfolio Pulse from Henry Khederian

June 11, 2024 | 5:52 pm

BioSig Technologies shares were halted on a circuit breaker due to a significant drop, with the stock now down by 40.2%.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 4:55 pm

On June 10, BioSig Technologies received a formal notice from the Nasdaq Hearings Panel that the company's common stock will be delisted.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 4:52 pm

The article highlights the intraday movements of 12 healthcare stocks on Tuesday. Notable gainers include Elutia, Trinity Biotech, and Akari Therapeutics, while significant losers include ProKidney, BioSig Technologies, and Inspire Veterinary.

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 4:31 pm

BioSig Technologies has appointed Mr. Ferdinand Groenewald as the interim Chief Financial Officer and Principal Accounting Officer. This leadership change could impact the company's financial strategy and operations.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 1:47 pm

The article highlights the intraday movements of 12 health care stocks on Thursday. Notable gainers include Cue Health (HLTH), OneMedNet (ONMD), iSpecimen (ISPC), Xeris Biopharma Holdings (XERS), Kintara Therapeutics (KTRA), and Lexaria Bioscience (LEXX). Significant losers include Sonoma Pharmaceuticals (SNOA), BioSig Technologies (BSGM), Mira Pharmaceuticals (MIRA), Innovative Eyewear (LUCY), Reshape Lifesciences (RSLS), and Dare Bioscience (DARE).

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 4:32 pm

BioSig Technologies (BSGM) shares fell by 17% to $1.99 after announcing a $3 million registered direct offering of 1,570,683 shares at $1.91 per share. Additionally, the company will issue unregistered warrants in a concurrent private placement. The proceeds will be used for working capital and general corporate purposes.

Portfolio Pulse from Henry Khederian

May 30, 2024 | 1:55 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.